N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

Sponsor: Sutro Biopharma, Inc. • ClinicalTrials.gov ID: NCT07227168

Registry updated: 2026-08-27
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a cohort expansion in 1 or more types of cancer to further evaluate a STRO-004 monotherapy dose, determine the best dose for use in later phases, and examine anti-tumor activity. * Part 1C is a dose escalation of STRO-004 combined with pembrolizumab to determine tolerability and preliminary anti-tumor activity of both drugs used together.

Interventions

  • STRO-004 (Drug)
    IV Infusion
  • Pembrolizumab (Drug)
    IV Infusion

Eligibility criteria

Inclusion Criteria: * Histologically or cytologically documented metastatic or locally advanced solid tumors including: Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Esophageal/Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Cervical Cancer, Endometrial Cancer, and Urothelial Carcinoma * Age 18 years or older * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 * Received all appropriate systemic therapies that are locally available for which they are eligible. For Parts 1A and 1C, there is no limit on the number of prior therapies. For Part 1B only, up to 3 prior therapies are allowed, except for NSCLC participants with genomic alterations, who may have up to 4 prior therapies * Availability of tumor tissue * Measurable disease per RECIST 1.1 * Adequate organ function * Participants receiving anticoagulants must be on a stable dose Exclusion Criteria: * Eye disorders * Untreated brain metastases * Pre-existing clinically significant ocular disorders, active interstitial lung disease, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition * Previous solid organ or bone marrow transplantation * Concurrent participation in another therapeutic treatment trial

Conditions

Head and Neck Squamous Cell Carcinoma HNSCC Non-Small Cell Lung Cancer NSCLC Esophageal Cancer Gastric Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma (PDAC) Cervical Cancer Endometrial Cancer Urothelial Cancer

Locations

  • UC San Diego Moores Cancer Center — San Diego, California, United States
  • SCRI Denver — Denver, Colorado, United States
  • Georgetown University Medical Center — Washington D.C., District of Columbia, United States
  • SCRI FCS Sarasota — Sarasota, Florida, United States
  • Mass General Cancer Center — Boston, Massachusetts, United States
  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai — New York, New York, United States
  • NEXT Austin — Austin, Texas, United States
  • NEXT San Antonio — San Antonio, Texas, United States
  • NEXT Virginia — Fairfax, Virginia, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record